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 Abstract: 
CHIP/STUB1 ubiquitin ligase is a negative co-chaperone for HSP90/HSC70, and 
its expression is reduced or lost in several cancers, including breast cancer. Using an 
extensive and well-annotated breast cancer tissue collection, we identified the loss of 
nuclear but not cytoplasmic CHIP to predict more aggressive tumorigenesis and shorter 
patient survival, with loss of CHIP in two-thirds of ErbB2+ and triple-negative breast 
cancers and in one-third of ER+ breast cancers. Reduced CHIP expression was seen in 
breast cancer patient-derived xenograft tumors and in ErbB2+ and triple-negative breast 
cancer cell lines. Ectopic CHIP expression in ErbB2+ lines suppressed in vitro oncogenic 
traits and in vivo xenograft tumor growth. An unbiased screen for CHIP-regulated 
nuclear transcription factors identified many candidates whose DNA-binding activity was 
up- or down-regulated by CHIP. We characterized Myeloid Zinc Finger 1 (MZF1) as a 
CHIP target given its recently identified role as a positive regulator of cathepsin B/L 
(CTSB/L)-mediated tumor cell invasion downstream of ErbB2. We show that CHIP 
negatively regulates CTSB/L expression in ErbB2+ and other breast cancer cell lines. 
CTSB inhibition abrogates invasion and matrix degradation in vitro and halts ErbB2+ 
breast cancer cell line xenograft growth. We conclude that loss of CHIP remodels the 
cellular transcriptome to unleash critical pro-oncogenic pathways, such as the matrix-
degrading enzymes of the cathepsin family, whose components can provide new 
therapeutic opportunities in breast and other cancers with loss of CHIP expression.   
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Introduction 
The ubiquitin-proteasome system (UPS) plays diverse roles in normal cellular 
homeostasis.  Ubiquitination involves two ubiquitin-activating (E1) enzymes, a small 
group of ubiquitin-conjugating (E2) enzymes and a large repertoire of ubiquitin ligase 
(E3) enzymes. E3s dictate substrate specificity and comprise two broad groups: the 
human papilloma virus E6-interacting (HECT) domain and the Really Interesting New 
Gene (RING) finger domain protein families (1). Consistent with roles of UPS in 
oncogenesis, certain cancers, e.g., multiple myeloma, are clinically treated with 
proteasome inhibitors (1). Recent focus has shifted to substrate-specific elements of the 
UPS, such as E3s, with MDM2 inhibitors currently in clinical trials for several 
malignancies (www.clinicaltrials.gov). Notably, mutations of E3s, such as CBL (2) or 
FBW7 (3) convert them into oncogenes. 
The C-terminus of HSC70-Interacting Protein (CHIP)/STIP1 homology and U-Box 
containing protein 1 (STUB1) is a U-box subfamily RING finger E3 that functions as a 
negative co-chaperone for the HSP90/HSC70 chaperone to regulate protein quality 
control by targeting unfolded or misfolded proteins for proteasomal degradation (4-9). 
CHIP also targets many mature proteins for ubiquitination and proteasomal degradation 
or degradation-independent regulation (10).  
CHIP targeting of oncogenic drivers/co-drivers, such as ErbB2, has prompted 
analyses of CHIP expression in human tumors. Analysis of matched normal and tumor 
tissues from 27 breast cancer patients revealed progressive loss of CHIP mRNA 
expression with tumor progression; CHIP knockdown in CHIP-high MCF-7 (ER+) cells 
increased and CHIP overexpression in CHIP-low MDA-MB231 (triple-negative; TN) cells 
suppressed oncogenic traits in vitro and xenograft tumor growth and metastasis in vivo 
(11). Another study of 33 normal and 127 breast tumor samples also showed an inverse 
relation of CHIP mRNA levels with increasing grade and Nottingham Prognostic Index 
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(12). A third study of 183 patients found an inverse correlation between ErbB2 and CHIP 
protein levels, with reduced CHIP expression associated with tumor progression (13). 
Thus, CHIP appears to function as a suppressor of breast cancer tumorigenesis. 
However, the extent of loss of CHIP expression in breast cancer subtypes is unknown. 
Mechanistically, CHIP can target cell surface, cytoplasmic, nuclear or secreted 
proteins for ubiquitin-dependent degradation (10). Relevant to breast cancer, CHIP 
targets ERRB2 (14-16), SRC-3 transcriptional coactivator (11), macrophage inhibitory 
factor (17), protein kinase 6/breast tumor kinase (18) and actin regulatory protein profilin-
1 (19).  However, how loss of CHIP promotes oncogenesis remains unclear. 
Here, we assessed both nuclear and cytoplasmic CHIP expression in a well-
annotated cohort of >900 breast cancer specimens. We show that a majority of ERBB2+ 
and TN, and a minority (but sizeable proportion of overall cases) of ER+ breast cancers 
show loss of CHIP expression, and that loss of the nuclear and not the cytoplasmic 
CHIP expression predicts features of tumor progression and invasion and shorter patient 
survival. Loss of CHIP expression in ERBB2+ breast tumor cell lines unleashed a 
program of increased tumor cell invasion and migration in vitro and tumorigenesis in 
vivo, as reported with a TN cell line model (11). Given the importance of the loss of 
nuclear CHIP, we performed an unbiased screen of the impact of low vs. high CHIP 
levels on DNA-binding activities of cellular transcription factors in ERBB2+ and TN 
breast cancer cell lines and identified many shared CHIP-regulated transcription factors. 
Here, we focus on CHIP regulation of MZF1 as it has been identified as a key mediator 
of pro-invasive signaling downstream of ERBB2 through upregulation of the expression 
of matrix degrading cathepsin B and L enzymes (20). We show the CHIP dependence of 
this pathway in cell lines representing various breast cancer subtypes and demonstrate 
that chemical targeting of CTSB inhibits the ERBB2-driven tumorigenesis. We conclude 
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that loss of CHIP expression unleashes a MZF1-dependent and CTSB/L-mediated pro-
oncogenic pathway in breast cancer. 
 
Materials and Methods 
Detailed methods are presented in Supplementary Methods.  
Cell culture: Culture of HEK-293T cells, ErbB2-overexpressing breast cancer cell lines 
SKBR3 and BT474 (ATCC) and 21MT1 (21), ER/PR+ MCF7 (ATCC) and TN MDA-
MB231 (ATCC) breast cancer cell lines, and their lentiviral infection to derive CHIP 
overexpressing or CHIP shRNA expressing lines are described in Supplementary 
Methods.  
Antibodies and Reagents: Rabbit anti-CHIP antibody used for blotting has been 
described (15). Other primary antibodies or secondary conjugates for fluorescence or 
immunoblotting analyses are described under Supplementary Methods.  
Cell lysis, immunoprecipitation and immunoblotting: Cells lysates were prepared in 
RIPA or Triton X-100 lysis buffers (as indicated in figure legends) and used for 
immunoprecipitation and immunoblotting analyses as described in Supplementary 
Methods. 
Quantitative real-time PCR: Total RNA was extracted using TRIzol reagent 
(Invitrogen), reverse transcribed using Quantitative real-time PCR kit (cat. 204141, 
Qiagen, Germantown, MD) and used for real-time QPCR with primers described in 
Supplementary Methods.  
Cell growth assays: Cell growth was analyzed as cumulative proliferation over 5 serial 
weekly passages and by soft agar anchorage-independent growth assay as described 
under Supplementary Methods. 
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 Transwell migration and invasion assays: The migration or invasion of cells was 
analyzed using uncoated or Matrigel-coated Transwell chambers as described under 
Supplementary Methods.  
Extracellular matrix (ECM) degradation assay: This assay was carried out using 
QCM™ Gelatin Invadopodia kit (Cat. ECM670, EMD Millipore, Billerica, MA) according 
to the manufacturer’s protocol, as described in Supplementary Methods. ECM 
degradation, seen as focal loss of fluorescent signal (“holes”) in the labeled gelatin layer, 
was quantified using Image J (NIH).  
Xenograft tumorigenesis: 106 cells in Matrigel (BD Biosciences) were implanted in the 
mammary fat pad of female NSG mice (The Jackson Laboratory) primed with s/c 
estrogen pellet (0.72 mg/60-day pellets; Innovative Research of America, Sarasota, FL) 
and tumor growth monitored weekly for 10 weeks.   After euthanasia, tumors were 
imaged, and formalin-fixed and paraffin-embedded for further analyses. Details are 
presented in Supplementary Methods. 
Protein/DNA array: A protein/DNA combo-array kit (Cat. MA1215, Affymetrix, Santa 
Clara, CA) was used to simultaneously screen 345 transcription factors for DNA-binding 
activity per vendor protocol with signals detected using chemiluminescence (See 
Supplementary Methods). 
Electrophoretic mobility shift assay (EMSA): EMSA was carried out using an EMSA 
kit (cat. 20148, Life Technologies, Waltham, MA) as described in Supplementary 
Methods.  
Cathepsin B (CTSB)/Cathepsin L (CTSL) activity assay: CTSB/L activity was 
assayed using the Magic Red CTSB/L Activity Kit (Cat. 937 & 941, Immunochemistry 
Technologies, Bloomington, MN) according to the manufacturer’s protocol (See 
Supplementary Methods). Experiments were run in triplicates and repeated thrice. Ten 
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random fields per well were imaged. Fluorescence intensity was quantified using Image 
J (NIH).  
GST fusion protein pulldown analyses: Cell lysate pulldown analyses of CHIP-MZF1 
interactions using GST-CHIP, GST-CHIP-H260Q/P269A mutant, GST-ΔU-box-CHIP 
(U-box domain deleted mutant) and GST-ΔTPR-CHIP (TPR domain deleted mutant 
CHIP) fusion proteins were done as described previously (15) (See Supplementary 
Methods.  
Human and animal subjects: The use of human tissues was approved by Nottingham 
Research Ethics Committee 2 under the title ‘Development of a molecular genetic 
classification of breast cancer’, and in compliance with current ethical and legal 
guidelines of the United Kingdom. All experiments in this study were conducted in 
accordance with the 1975 Helsinki declaration and its later amendments or comparable 
ethical standards. There was written consent obtained from patients at the time of 
collection of the material. The use of human tissues was approved by the Ethics 
Committee of the University of Nottingham. Mouse studies were pre-approved by the 
UNMC Institutional Review Board (IRB) Committee, in compliance with Federal and 
State guidelines. 
IHC analysis of breast cancer tissue microarrays:  Tissue microarrays (TMAs) 
corresponding to a well-annotated 971 breast cancer patient cohort at the University of 
Nottingham Hospital Breast Unit and a commercial TMA (BR20837, from US Biomax, 
INC.) were analyzed by IHC staining (see Supplementary Methods for details) with a 
previously described (22) anti-rabbit CHIP antibody that was further validated 
(Supplementary Figure 1).  
 
Results 
Running title: Loss of CHIP E3 unleashes MZF1-cathepsin axis 
 8 
 
Reduced nuclear CHIP expression in breast cancer correlates with tumor 
progression, invasion and poorer patient survival 
As previous small studies (11-13) have not clarified which breast cancer 
subtypes lose CHIP expression, we performed IHC analysis of formalin-fixed and 
paraffin-embedded tissue microarrays (TMAs) from a well-annotated cohort of 971 
breast cancer patients (Supplementary Table 1) (23-27) using an established rabbit anti-
CHIP antibody (15) further validated in western blotting with lysates of CHIP-depleted or 
ectopic CHIP-expressing cell lines (Supplementary Figure S1). Initial IHC of a 
commercial breast cancer TMA (208 samples) detected both cytoplasmic and nuclear 
CHIP within tumor cells and in surrounding normal epithelium (Figure 1A). In the 971-
sample TMA, 423 and 314 samples, respectively, were evaluable for cytoplasmic and 
nuclear staining, with multiple staining patterns: low cytoplasmic/low nuclear, high 
cytoplasmic/low nuclear, low cytoplasmic/high nuclear; or high cytoplasmic/high nuclear 
(Figure 1B; Supplementary Table1). Loss of nuclear CHIP staining showed a significant 
positive correlation with biochemical markers of tumor progression and metastasis, 
reduced ER and PR staining, altered cytokeratins (CK18, CK19), increased expression 
of early epithelial-mesenchymal transition markers (N-cadherin, P-cadherin) and 
expression of EGFR family proteins (EGFR, ErbB2, ErbB4) (Supplementary Table 2). 
Only CK18 (p=0.001) and ErbB2 (p=0.016) expression correlated with reduced 
cytoplasmic CHIP staining (Supplementary Table 2). Lower nuclear but not cytoplasmic 
CHIP staining showed a significant positive correlation with clinical-pathological features 
of tumor progression (higher tumor size, tumor grade, pleomorphism and mitotic status) 
(Supplementary Table 1). Kaplan-Meier analysis revealed that low nuclear but not the 
cytoplasmic staining pattern correlated significantly with poorer breast cancer-specific 
survival (Nuclear CHIP, p=0.003 Vs. cytoplasmic CHIP, p=0.469; Figure 1C). Using the 
Running title: Loss of CHIP E3 unleashes MZF1-cathepsin axis 
 9 
previously-established ER, PR and ErbB2/Her2 expression status of the TMA samples 
(24-28), low CHIP expression was seen in two-thirds of ErbB2+ and TN cases and about 
one-third of ER+ cases.  
 
CHIP suppresses tumorigenic traits in ErbB2+ breast cancer cell lines 
Validating IHC results, most ErbB2+ and TN breast cancer cell lines showed 
lower CHIP mRNA and protein levels compared with ER+ lines (Supplementary Figure 
S2A and S2B); the ER+ and TN cell line results confirm a previous report (11). Western 
blotting of 12 breast cancer patient-derived xenograft (28) lysates confirmed the lower or 
absent CHIP expression in TN, ErbB2+ and some ER+ breast cancers (Supplementary 
Figure S2C). The CHIP expression status in the commercial TMA was consistent with 
these results (Supplementary Figure S2D). 
To gain mechanistic insights into how the loss of nuclear CHIP promotes 
oncogenic progression, we utilized ErbB2+ breast cancer cell lines (BT474, SK-BR3 and 
21-MT1) as primary models, confirming key findings in TN (MDA-MB231) and ER+ 
(MCF-7) lines. We engineered the ErbB2+ and TN lines to stably overexpress Myc-CHIP 
(CHIP-hi lines) (or vector control; CHIP-lo lines) and MCF-7 cells with CHIP shRNA 
(CHIP-lo) to deplete the endogenous CHIP expression (or a control shRNA; CHIP-hi) 
(Supplementary Figure S1A). Of note, Myc-CHIP is seen as multiple bands, some 
migrating considerably slowly while others co-migrating with endogenous CHIP; the 
authenticity of these bands as Myc-CHIP is demonstrated by anti-Myc immunoblotting 
(Supplementary. Figure S1C). As CHIP expression in MDA-MB-231 cells is known to 
suppress oncogenic attributes (11), these served as controls. 
While no significant differences in cell proliferation were observed over a single 
passage, confirming previous MDA-MB231 results (11), cumulative cell proliferation over 
multiple passages was modestly but significantly lower in CHIP-hi vs. control cells 
Running title: Loss of CHIP E3 unleashes MZF1-cathepsin axis 
 10 
(Figure 2A). CHIP-high cells exhibited a significantly lower number of colonies in soft 
(Figure 2B), significantly reduced Transwell migration (Figure 2C), and significantly 
reduced invasion through Matrigel (Figure 2D) compared to CHIP-lo control cells. 
Analysis of CHIP-lo vs. CHIP-hi MDA-MB231 cells, as controls, confirmed the 
expected reduction in primary tumor growth and lung metastasis upon CHIP 
overexpression (11) (Supplementary Figure S3A, S3B). Notably, the CHIP-hi BT474 
cells formed significantly smaller xenograft tumors compared to those with CHIP-lo cells 
(Figure 3A and 3B). Exogenous CHIP overexpression in tumors was confirmed by 
western blotting (Figure 3C). Histologically, the CHIP-hi BT474 tumors showed lower 
nuclear atypia and mitotic index (Figure 3D and 3E), and reduced Ki67+ proliferating 
cells (Figure 3F and 3G) compared to CHIP-lo BT474 tumors. No significant difference in 
immunostaining for the apoptotic marker cleaved-caspase 3 was noted (Figure 3F and 
3H), suggesting a primarily cytostatic impact of CHIP overexpression. These studies 
support the tumor suppressor role of CHIP in ErbB2+ breast cancer as suggested by our 
clinical-pathological analyses. 
 
Identification of nuclear targets of CHIP in breast cancer 
As loss of nuclear but not cytoplasmic CHIP expression predicted tumor 
progression and poor patient outcomes, we assessed the cognate DNA-binding activities 
of 345 cellular transcription factors in nuclear extracts of control vs. CHIP-hi ErbB2+ 
BT474 cells, using a commercially-available array platform. The DNA-binding activity in 
CHIP-hi over CHIP-lo extracts was expressed as a fold ratio. Subsets of transcription 
factors showed changes in DNA-binding activities outside of the arbitrary 3-fold cut-off, 
representing potential direct or indirect targets of negative or positive regulation by CHIP 
(Figure 4A, left). These (Supplementary Table 3) included known CHIP targets, such as 
p53 and NFkB (29, 30), validating the approach. Analysis of CHIP-hi vs. CHIP-lo 
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(control) MDA-MB231 cells (Figure 4A, bottom) showed that most CHIP targets were 
shared with the BT474 cell model (see Supplementary Table 4) (Fig 4A), although the 
extent of changes differed. Immunoblot analysis of a sample of known and novel 
transcription factors identified as CHIP targets (NFB p69/p60, Stat3, FOXM1, MZF1) 
confirmed their downregulation in CHIP-hi vs. CHIP-lo BT474 and MDA-MB231 cell lines 
(Fig. 4B, 4C). Thus, our unbiased screen identified novel CHIP-targeted transcription 
factors whose deregulated function upon loss of CHIP expression may contribute to 
tumor progression. 
 
MZF1 is a direct target of CHIP-mediated ubiquitination and degradation 
We focused further on myeloid zinc finger 1 (MZF1), whose DNA-binding activity 
was down-regulated in CHIP-hi BT474 and MDA-MB231 cells (Figure 4A; MZF1 
highlighted in white), as it was recently identified as a nexus of ErbB2 signaling that 
culminates in tumor cell invasiveness through increased transcription of matrix-
degrading enzymes cathepsin B (CTSB) and L (CTSL) (20). Electrophoresis mobility 
shift assay (EMSA) using sequences corresponding to MZF1 binding sites on the CD34 
gene promoter (31) confirmed reduced binding activity (shifted bands) in CHIP-hi vs. 
CHIP-lo BT474 cells (Figure 4D). The MZF1 mRNA level was reduced in CHIP-hi vs. 
CHIP-lo cells BT474 cells (Figure 4E), suggesting the regulation of upstream modulators 
of MZF1 transcription as part of CHIP-dependent reduction in DNA-binding activity. 
MZF1 protein level was reduced in CHIP-hi vs. CHIP-lo cells, and anti-ubiquitin blotting 
of MZF1 immunoprecipitations showed increased MZF1 ubiquitination in CHIP-hi vs 
CHIP-lo BT474 cells (Figure 4F). Co-transfection of CHIP and MZF1 in HEK-293T cells 
revealed CHIP dose-dependent MZF1 ubiquitination (Figure 4G, upper) and reduction in 
protein level (Figure 4G, bottom). Notably, while ErbB2 levels in CHIP plus ErbB2 co-
transfected HEK-293T cells increased upon treatment with MG132 (proteasomal 
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inhibitor) (Supplementary Figure S4D, S4E), as expected (14, 15), MG132 treatment 
failed to rescue the MZF1 levels in CHIP co-transfected cells (Figure 4H, J), suggesting 
the possibility that MZF1 degradation occurs through chaperone-mediated autophagy in 
lysosomes as demonstrated for CHIP targets such as HIF-1 (32). Indeed, CHIP-
induced reduction in MZF1 levels was partially rescued by a short treatment of cells with 
the lysosomal inhibitor bafilomycin A1 (Figure 4I, K). Finally, depletion of endogenous 
CHIP by shRNA knockdown in MCF-7 cells led to upregulation of MZF1 and CTSB/L 
protein levels (Supplementary Figure S4B). These results support the conclusion that 
MZF1 is a bona-fide target of CHIP, involving indirect transcriptional downregulation and 
CHIP-dependent ubiquitination and lysosomal degradation of MZF1. 
The Tetratricopetide repeat (TPR) domain of CHIP is required for interaction with 
MZF1  
The TPR domain of CHIP has been shown to mediate binding to most interacting 
partners such as HSC70 and HSP90 (4, 15). Given the CHIP-MZF1 co-
immunoprecipitation (Figure 4G), we used GST fusion proteins of intact CHIP or its point 
or deletion mutants for pulldown of MZF1 from lysates of HEK-293T cells transiently 
transfected with MZF1 to map the CHIP domain that mediates its interaction with MZF1. 
Compared to the negative control GST, GST-CHIP robustly pulled down MZF1 from cell 
lysates (Figure 4L). Notably, the U-box point mutant (GST-CHIP-H260Q/P269A) and the 
U-box domain deleted CHIP mutant (GST-ΔU box-CHIP) showed unimpaired MZF1 
pulldown, while no pulldown was seen with the TPR domain deleted CHIP (GST-ΔTPR-
CHIP) (Figure 4L). These results establish that CHIP binds to MZF1 through its TPR 
domain. 
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CHIP is a negative regulator of MZF1-dependent and Cathepsin B/L-mediated ECM 
degradation 
CTSB/L are key regulators of tumor invasion, angiogenesis and metastasis (33), 
and their MZF1-dependent transcriptional upregulation was shown to mediate in vitro 
tumor cell invasion upon ErbB2 overexpression in breast cancer cells (20). We therefore 
asked if CHIP regulation of MZF1 translates into control of CTSB/L expression. EMSA 
with a DNA probe from a known MZF1-binding site in the CTSB promoter (31) confirmed 
reduced DNA-binding activity in the nuclear extracts of CHIP-hi vs. control ErbB2+ cells 
(Figure 5A), with reduced CTSB and CTSL mRNA and protein levels (Figure 5B, 5D, 
and 5E), reduced CTSB/L enzymatic activities (Figure 5G and 5I) measured with a 
fluorescent substrate (34), and reduced FITC-labeled gelatin degradation (35, 36) 
(Figure 6A and 6C). Thus, the MZF1/CTSB/L pro-invasion signaling axis is negatively 
regulated by CHIP in ErbB2+ breast cancer cells. 
Consistent with CHIP-dependent reduction in the DNA-binding activity of MZF1 in 
CHIP-hi vs. CHIP-lo MDA-MB231 cells (Figure 4A), reduced mRNA and protein levels of 
CTSB/L (Figure 5C and 5F), reduced CTSB/L activity (Figure 5H and 5J) and reduced 
florescent gelatin degradation (Figure 6B and 6D) were observed in CHIP-hi vs. CHIP-lo 
MDA-MB231 cells. Increased CTSB/L expression was also seen in CHIP KD vs. control 
MCF7 cells (Supplementary Figure S4B).   Ectopic overexpression of MZF1 in CHIP-hi 
as well as CHIP-lo MDA-MB231 cells increased the florescent gelatin degradation 
(Figure 6 E and F). Finally, treatment of CHIP-lo 21MT1 cells (high CTSB/L activity; 
Figure 6A and 6C) with CA074, a specific inhibitor of CTSB (37), abrogated the 
fluorescent gelatin degradation, and markedly inhibited the Transwell invasion of 21MT1 
(Figure 7A-C) and MDA-MB-231 (7D-F) breast cancer cell lines. Thus, we conclude that 
loss of CHIP expression across breast cancer subtypes upregulates the pro-invasive 
MZF1-CTSB/L signaling axis. 
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To assess if the upregulation of CTSB expression and activity as a result of CHIP 
downregulation contributes to oncogenesis in vivo, we grew BT474 xenograft tumors to 
an average of 0.5 mm3 and treated the mice with CA074 (25 mg/Kg body weight, i.p.), 
Trastuzumab (4 mg/Kg, tail vein injection) as a standard ErbB2-targeted therapeutic or 
the vehicle control, based on previously used dosages (37-39). CA074 treatment led to a 
marked and statistically-significant inhibition of tumor growth at multiple time points, 
comparable to that seen with Trastuzumab (Figure 7G), supporting the conclusion that 
one mechanism by which loss of CHIP promotes breast tumor progression is by 
eliminating the negative regulation of MZF1 and unleashing the cathepsin expression. 
 
Discussion 
Loss of expression of the HSP90/HSC70 co-chaperone CHIP E3 has emerged 
as a mechanism to promote tumor progression. Here, we demonstrate that loss of 
nuclear, and not cytoplasmic, CHIP expression is associated with tumor progression and 
shorter survival in breast cancer patients and is a feature of about two-thirds of ErbB2+ 
and TN as well as a third of ER+ breast cancers. Importantly, we identify loss of CHIP as 
a key mechanism to alter the DNA-binding activities of a substantial subset of cellular 
transcription factors and establish that loss of CHIP expression unleashes a pro-invasion 
signaling cascade in which the CHIP target MZF1 promotes cathepsin B and L 
expression. Using a chemical inhibitor strategy, we show that upregulation of MZF1-
CTSB axis due to loss of CHIP expression contributes to tumorigenesis. 
IHC analyses of an extensive collection of well-annotated breast cancer TMAs 
demonstrated that loss of nuclear CHIP signals correlates with markers of advanced 
tumor progression, including higher tumor grade, mitotic index and markers of early EMT 
(Supplementary Table 1), and significantly shorter breast cancer-specific and 
progression-free survival (Figure 1C). Loss of nuclear CHIP was a feature of nearly two-
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thirds of ErB2+ and TN subtypes, consistent with their poorer intrinsic patient outcomes 
and higher metastatic odds (40, 41), and about a third of ER+ breast cancers 
(Supplementary Table 2). In contrast, loss of cytoplasmic CHIP expression was only 
associated with ErbB2 positivity and did not predict poor patient survival (Figure 1C). 
These results materially extend previous findings using smaller patient cohorts (11-13), 
and highlight the subtype preference of CHIP loss and the importance of the loss of 
nuclear CHIP as a pro-oncogenic adaptation in breast cancer. Of note, the CHIP-low 
ER+ patients numerically exceed the CHIP-lo ErbB2+ and TN patients, and further 
studies are needed to assess if these patients belong to a specific molecular sub-class. 
Based on previous publications (11) and our results on cell lines (Supplementary Figure 
S2D), reduced CHIP mRNA expression provides one mechanism for reduced CHIP 
levels in tumors. Why nuclear CHIP levels maybe selectively reduced in certain primary 
tumors is not clear at present. Mechanisms such as aberrant nuclear/cytoplasmic 
transport of CHIP or selective degradation of CHIP within the nucleus or cytoplasm will 
need to be explored as a potential basis for our new findings. 
 Analyses in breast cancer cell lines confirmed the predominant loss of CHIP 
expression in the ErbB2+ and TN subtypes. Using matched pairs of ErbB2+ breast 
cancer cell lines with low endogenous CHIP expression vs. their CHIP-hi derivatives in 
functional assays, we show that CHIP levels are a key determinant of ErbB2-driven cell 
growth and invasiveness in vitro and xenograft tumor growth in nude mice, extending 
previous findings using CHIP-reconstituted MDA-MB231 (TN) and CHIP-depleted MCF-
7 (ER+) lines (11), which served as controls. While we confirmed the lack of impact of 
CHIP restoration on cell proliferation in a single passage (11), analyses over multiple 
passages revealed a subtle but significant proliferative disadvantage (Figure 2A), which 
is profound under anchorage-independent conditions (Figure 2B). Thus, CHIP serves as 
a tumor suppressor for ErbB2+, TN and a proportion of ER+ breast cancers. 
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Furthering our novel findings that loss of nuclear and not cytoplasmic CHIP 
correlates with tumor progression, an unbiased protein/DNA array screen identified a 
number of transcription factors whose DNA-binding activities are directly or indirectly up- 
or down-regulated by CHIP (Figure 4A), vastly expanding the list of potential targets of 
CHIP in the context of cancer (29, 30). Here, we have focused on MZF1, whose activity 
was downregulated by CHIP, since it was recently identified as a major transcriptional 
activator of CTSB//L-mediated tumor cell invasion downstream of ErbB2 in breast cancer 
cells (42). CTSB/L are overexpressed in primary breast cancers and CTSB or MZF1 
knockdown abrogated breast cancer cell invasiveness in vitro (41).  Our EMSA analyses 
confirmed the reduced MZF1 DNA-binding activity in CHIP-hi breast cancer cells (Figure 
4D), and we show that MZF1 is both a direct target of CHIP for ubiquitination and 
destabilization (Figure 4F and 4G), and also indirectly regulated at the mRNA level, 
potentially due to CHIP regulation of upstream regulators of MZF1 expression such as 
MYC (43) (Figure 4A). Regarding indirect transcriptional regulation of MZF1 by CHIP, 
several transcription factors targeted by CHIP, including STAT 1/3 and ATF (Figure 4 A-
C; and Supplementary Table 3 and 4), have binding sites within the MZF1 promoter 
region (data not shown) and their downregulation by CHIP could contribute to reduced 
MZF1 expression. 
We show that MZF1 and CHIP associate with each other (Fig. 4G) and used 
GST pulldown assays to identify the TPR domain of CHIP to mediate interaction with 
MZF1 (Fig. 4L). Notably, our analyses using proteasomal (MG132) and lysosomal 
(Bafilomycin A) inhibitors show that CHIP-dependent destabilization of MZF1 protein 
primarily occurs in the lysosome (Fig 4I). It is likely that the lysosomal degradation of 
MZF1 reflects CHIP-dependent chaperone-mediated autophagy as demonstrated for 
HIF1a and other targets (32). In this regard, MZF1 possesses several sequences 
QSFRQ and KAFRQ (sequences that identified 447-451, 548-552, 576-580, 660-664, 
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688-692 amino acids) homologous to the motif KFERQ found in other chaperone-
mediated autophagy targets (32). Since intermediary kinases (CDC42BPβ, ERK2, 
PAK4, PKCα) were implicated in MZF1-mediated CTSB/L transcription downstream of 
ErbB2 (41), negative regulation of these kinases or ErbB2 (14, 15) may also contribute 
to CHIP regulation of MZF1. 
Our analyses support a key role of loss of CHIP as a mechanism to unleash the 
MZF1-dependent transcriptional network that controls CTSB/L expression (Figure 5) and 
extracellular matrix (ECM) degradation (Figure 6), and to promote oncogenesis (Figure 
2). CTSB is a well-established downstream mediator of invasive/metastatic signaling in 
various cancers (44, 45), including breast cancer (20, 36). Specific CTSB inhibition with 
CA074 reduced the matrix degradation and cell invasion in vitro and tumor growth in vivo 
(Figure 7), providing further support for loss of CHIP expression as a key breast cancer 
adaptation to unleash the pro-oncogenic MZF1-CTSB pathway. The strong effect of 
CTSB inhibition alone on matrix degradation and xenograft tumor growth, the latter 
comparable to Trastuzumab (Figure 7D), suggests that CTSB may be the dominant 
player in BT474 cells, consistent with strong reported impact of CTSB depletion on in 
vitro invasiveness of ErbB2+ breast cancer cell lines (42). However, further studies to 
assess the contribution of CTSL and other potential targets of MZF1 are warranted. Our 
in vitro results in TN and ER+ cell lines (Figure 4) also support the unleashing of MZF1-
CTSB/L pathway in the corresponding breast cancer subtypes, and further studies in 
these and other tumors with loss of CHIP expression (10) will be of interest. Of note, 
TCGA breast cancer data analysis (eBioportal) did not, however, reveal a positive 
correlation between CTSB/L and MZF1 mRNA expression (in fact we noted moderate 
negative Pearson correlation coefficients). We surmise that MZF1 and/or CTSB/L 
expressed in myeloid lineage and potentially other stromal components may contribute 
to this discrepancy. Transcriptomic analysis of laser capture micro-dissected tumor 
Running title: Loss of CHIP E3 unleashes MZF1-cathepsin axis 
 18 
samples or multi-color IHC with lineage markers will be necessary to further assess the 
relationship between MZF1 and CTSB/L expression in relation to CHIP/STUB1 
expression in primary tumors. 
 
In conclusion, our studies demonstrate that upregulation of MZF1/CTSB/L axis is 
an important pro-oncogenic mechanism unleashed by loss of CHIP expression in breast 
cancer. Given the established roles of cathepsins in matrix remodeling, invasion, 
angiogenesis and metastasis (44, 45), future studies to establish the role and targeting 
of MZF1-CTSB/L axis in metastatic tumor settings may provide new therapeutic 
opportunities for breast and other tumors with loss of CHIP expression (30, 46-49). 
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Figure Legends 
 
Figure 1. Reduced nuclear CHIP staining in primary breast cancer tissue microarray 
(TMA) specimens. (A) Anti-CHIP IHC staining of a representative breast cancer 
specimen (top) vs. normal breast tissue (bottom) to show cytoplasmic and nuclear staining. 
(B) Representative pictures depicting low or high nuclear vs. cytoplasmic CHIP staining 
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patterns in breast cancer TMAs. (C) Kaplan-Meier analysis correlating breast cancer-
specific survival (BCSS) with moderate/high vs. negative/low nuclear (left) or cytoplasmic 
(right) CHIP staining in TMA samples. Number of patients in each group are shown in 
parentheses next to captions. P values are indicated inside each box. 
 
Figure 2. Suppression of in vitro oncogenic attributes upon CHIP overexpression 
in CHIP-lo ErbB2+ breast cancer cell lines. (A) Cumulative proliferation of CHIP-lo 
control (MSCV-puro) vs. CHIP-hi (MSCV-CHIP) 21MT1, BT474 and SKBR3 cell lines. 
Data points represent cumulative cell numbers with each serial passage. (B) Anchorage-
independent cell growth in soft agar after 3 weeks of culture. Y-axis, number of colonies 
per 2500 seeded cells. (C) Transwell cell migration assay. 2000 cells were added in top 
chamber and migration scored after 24 hrs. Y-axis, number of migrated cells per high 
power field (HPF). (D) Matrigel-coated Transwell invasion assay. 2000 cells were added 
in top chamber and migration scored after 24 hrs. Y-axis, number of migrated cells per 
HPF.  Data in each figure represent mean +/- SEM of 3 experiments, each in triplicates. 
 
Figure 3. Reduced xenograft growth of CHIP-overexpressing BT474 cells in nude 
mice. (A) Tumor volume of CHIP-lo (MSCV-puro) control and CHIP-hi (MSCV-CHIP) 
BT474 xenografts over time. Mean+/- SEM, N = 6 per group., * = p<0.05, ** = p<0.01, *** 
= p<0.001. (B) Photograph of resected CHIP-lo (upper) and CHIP-hi (lower) BT474 cell 
xenografts. (C) Western blotting to visualize the endogenous and overexpressed (Myc-
tagged) CHIP in resected BT474 xenografts; HSC70, loading control. (D) Representative 
H&E staining and mitotic events (red circles) of CHIP-lo (left) and CHIP-hi (right) BT474 
xenograft tumor sections. (E) Quantification of mitotic events of sections depicted in D. 
Mean +/- SEM, n=3. (F) Ki67 (brown) and cleaved caspase 3 (CC3; red) co-staining of 
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CHIP-lo (left) and CHIP-hi (right) BT474 xenograft tumor sections. (G, H) Quantification 
of Ki67 (G) and CC3 (H) positive cells depicted in F. Mean +/- SD, n=4. 
 
Figure 4. Identification of MZF1 as a CHIP-regulated transcription factor in breast 
cancer cells. (A) DNA-binding activities of 345 transcription factors were analyzed in 
nuclear extracts of CHIP-lo (MSCV-puro control) vs. CHIP-hi (MSCV-CHIP) BT474 and 
MDA-MB-231 cell lines. Y-axis, loge-fold binding in CHIP-hi over CHIP-lo cells. The 3-
fold increase (upper) or decrease (lower) in binding (dotted lines) was used as cut-off. 
MZF1 (Open symbol). (B, C) Validation of CHIP-dependent downregulation of protein 
levels of selected transcription factors identified in A by western blotting of CHIP-lo vs. 
CHIP-hi BT474 (B) or MDA-MB-231 (C) cell lysates. (D) Real-time qPCR analysis of 
MZF1 mRNA levels in CHIP-hi vs. CHIP-lo BT474 cells.  (E) A biotin-labeled double-
stranded oligonucleotide with MZF1-specific DNA sequence was used to probe nuclear 
extracts of CHIP-hi (MSCV-CHIP, C) vs. CHIP-lo (MSCV-puro, P) BT474 cells. 200-fold 
excess of the non-labeled oligonucleotide served as a competitor. (F) Immunoblot 
analysis of MZF1 protein levels in CHIP-hi vs. CHIP-lo BT474 cells. (G) CHIP-dependent 
ubiquitination and degradation of MZF1. Anti-MZF1 immunoprecipitations from lysates of 
HEK-293T cells transfected with GFP-MZF1 (1g) +/- Myc-CHIP (1 or 2 g) were 
immunoblotted for ubiquitin or MZF1 (upper panel), and whole cell lysates (lower panel) 
were blotted for MZF1, CHIP or HSC70 (loading control). (H, I) HEK-293T cells were 
transfected with MZF1-GFP (250 ng) +/- Myc-CHIP (1 g). Cells were treated with 
vehicle (-) or proteasomal inhibitor MG132 (50 M) or lysosomal inhibitor bafilomycin A1 
(100 nM) for 6 or 16 hr., respectively. Lysates were immunoblotted for MZF1 or CHIP. (J, 
K) Quantitation of the MZF1 levels in CHIP-co-transfected cells in the presence of 
MG132 or Bafilomycin A1, relative to vehicle controls assigned a value of 1. Data shown 
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represent mean +/- S.D. of n=3; * = p<0.05, ** = p<0.01, *** = p<0.001. (L) The 
tetratricopeptide repeat (TPR) domain of CHIP is required for binding to MZF1. HEK-
293T cells transfected with MZF1-GFP and their lysates used for pulldown with GST or 
the indicated GST-CHIP fusion proteins. Bound MZF1-GFP was visualized by 
immunoblotting for GFP (upper panel) or MZF1 (middle panel). Ponceau Red staining of 
the membrane shows the relative amounts of fusion proteins used in pulldowns (lower 
panel). 
 
Figure 5. CHIP levels control the expression of MZF1 target genes cathepsins B 
and L. (A) EMSA analysis with the CTSB promoter sequence in CHIP-hi vs. CHIP-lo 
BT474 cells was done as in Figure 4B. (B, C) CTSB/L mRNA expression in CHIP-hi vs. 
CHIP-lo BT474 (B) and MDA-MB-231 (C) cells was analyzed by real-time qPCR; n=3. 
(D, E) Immunoblotting for CTSB (D) and CTSL (E) protein levels in CHIP-hi vs. CHIP-lo 
BT474 cells. (F) Immuno-histochemical analysis of MZF1 (left panel), CTSB (middle 
panel), and CTSL (right panel) in CHIP-hi vs. CHIP-lo MDA-MB-231 cells. (G,H) CTSB/L 
activities in CHIP-hi vs. CHIP-lo 21MT1 (G) and MDA-MB-231 (H) cells analyzed by the 
production of a red fluorescent cleavage product. (I,J) Quantification of CTSB (top) and 
CTSL (lower) activities presented in G and H panels in CHIP-hi vs CHIP-lo 21MT1 (I) 
and MDA-MB-231 (J) cells. Each square represents one replicate. Mean +/- S.D. shown; 
* = p<0.05; ** = p<0.01; *** = p<0.005. 
 
Figure 6. The CHIP-MZF1-CTSB axis influences tumor cell invasiveness. (A,B) 
Degradation of FITC-labeled gelatin matrix (seen as patchy holes in the uniform green 
matrix) by CHIP-lo vs. CHIP-hi 21MT1 (A) and MDA-MB-231 (B) cells seeded for 48 
hours and stained for actin-containing invadopodia with phalloidin (red) and for nuclei 
with DAPI (blue). (C, D) Quantification of gelatin degradation presented in A (C) and B 
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(D).  Mean +/- SD., n=4. (E)  Restoration of FITC-labeled gelatin matrix degradation by 
MZF-1 overexpression in CHIP-hi MDA-MB-231 cells. Stably MZF-1 overexpressing 
CHHIP-lo or CHIP-hi MDA-MB231 cells were analyzed as in A and B. (F) Quantification 
of gelatin degradation shown in E. Each square represents a replicate. Mean +/- SD., 
shown, * = p<0.05, ** = p<0.01, *** = p<0.005. (G) Western blotting of MZF1 
overexpression in CHIP-lo vs. CHIP-hi MDA-MB-231 cells. (H, n=3) Quantification of 
MZF1 overexpression shown in G; n=3. 
 
Figure 7. CTSB inhibition reduces ErbB2+ breast cancer cell tumorigenesis. (A) 
21MT1 cells cultured on FITC-gelatin were treated with DMSO vehicle or CTSB inhibitor 
(CA074; 25 g/ml) for 48h and degradation analyzed as in Figure 5G. (B) Quantification 
of FITC-gelatin degradation shown in 7A. Mean + S.D., n=4. (C) 21MT1 cells seeded on 
Matrigel-coated Transwell invasion membranes were treated with DMSO (control) or 
CA074 (25 g/ml) for 24h, and cells that had invaded through Matrigel to the bottom 
surface were stained with CyQuant GR fluorescent dye and quantified using a 
fluorescence reader. Mean + S.D., n=3. (D) FITC-gelatin matrix degradation by MDA-
MB-231 cells was analyzed after 48h culture in DMSO (control) or CTSB inhibitor 
(CA074; 25g /ml) as in Figure 5G. (E) Quantification of FITC-gelatin degradation shown 
in 7D. Mean + S.D., n=4. (F) Invasion of MDA-MB-231 cells incubated with DMSO 
(control) or CA074 (25 m/ml) as in Fig. 6C. Mean + S.D., n=8. (G) Groups of 9 nude 
mice carrying BT474 xenografts (average 0.5 cm3 size) received Trastuzumab (via tail 
vein; 4 mg/kg every 4 days), CA074 (i.p., 25 mg/kg in saline daily) or saline (control), 
and tumor volumes were monitored every other day. Mean +/- SEM., n=9; * = p<0.05, ** 
= p<0.01, *** = p<0.001.  
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